Last checked at 23 May 2017 07:00
23 May 2017
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Oxford BioDynamics enters into development agreement with two top 10 global pharmaceutical companies
New collaborators add further validation to EpiSwitch™ platform
Oxford BioDynamics Plc (AIM: OBD), a revenue-generating biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, announces that it has entered into a development agreement with two of the top 10 global pharmaceutical companies, that are collaborating on an anti PD-L1 therapy. Oxford BioDynamics will identify biomarkers in whole blood of non-small cell lung carcinoma (NSCLC) patients to assist in differentiating between responders and non-responders to an anti PD-L1 therapy, using its EpiSwitch™ biomarker platform.
The agreement has the potential to be extended in the form of a licensing agreement, which would see the development of an EpiSwitch™-class blood-based test, based on the work undertaken as part of the current agreement, for use by the pharmaceutical companies.
Financial terms of the agreement are not disclosed.
Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:
"We are very pleased to be working with these prestigious pharmaceutical companies to help them differentiate between responders and non-responders to an anti PD-L1 therapy. The momentum of EpiSwitch™, as the leading epigenetic platform, continues to grow and the fact that our EpiSwitch™ platform is ideally positioned to aid these pharmaceutical companies only validates the platform further. We are excited by the potential of this agreement and we look forward to working with these companies with the aim of improving their development outcomes."
-ENDS-
For further details contact:
Oxford BioDynamics Plc |
| +44 (0)1865 518910 |
Christian Hoyer Millar, CEO |
|
|
Katie Long, CFO |
|
|
|
|
|
Stifel Nicolaus Europe Limited |
| +44 (0)20 7710 7600 |
Nominated Advisor and Broker |
|
|
David Arch |
|
|
Jonathan Senior |
|
|
Peter Lees |
|
|
Ben Maddison |
|
|
|
|
|
Shore Capital |
| +44 (0)20 7408 4090 |
Joint Broker |
|
|
Bidhi Bhoma |
|
|
Edward Mansfield |
|
|
|
|
|
FTI Consulting |
| +44 (0)20 3727 1000 |
Financial Public Relations Advisor |
|
|
Julia Phillips |
|
|
Brett Pollard |
|
|
Natalie Garland-Collins |
|
|
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue‐generating biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.